Biotech IV Monitor

LQDA — Liquidia Corporation

$7.7B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Liquidia Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.

Next readoutFebruary 2027in ~3 months
Upcoming readouts21 Phase 3
Market cap$7.7B
Cash & investments$396M~2 quarters at last loss rate
Recent 8-K filings1latest 2026-11-10

Upcoming readouts

Phase 2 LIQ861 (treprostinil) inhalation powder
Raynaud's Phenomenon Secondary to Systemic Sclerosis · NCT07748000
February 2027
Not Yet Recruiting
Phase 3 L606
Pulmonary Hypertension Due to Lung Disease (Disorder) · NCT07285655
July 2029
Recruiting

Cash position

Liquidia Corporation reported $396M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $236M; at that rate the cash would last about 2 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-10

Companies working on similar indications

Discussion

No messages yet. If you follow LQDA, you can start the conversation.
Track LQDA in real time
See live implied volatility for LQDA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on LQDA
Contact — questions or corrections about LQDA: dukeupt@gmail.com